GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » Receivables Turnover
Switch to:

Biohaven (NYSE:BHVN) Receivables Turnover

: 0.00 (As of Sep. 2022)
View and export this data going back to 2022. Start your Free Trial

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biohaven's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Biohaven's average Accounts Receivable for the three months ended in Sep. 2022 was $0.00 Mil.


Biohaven Receivables Turnover Historical Data

The historical data trend for Biohaven's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data
Trend Dec20 Dec21
Receivables Turnover
- -

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22
Receivables Turnover Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Biohaven's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven Receivables Turnover Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Biohaven's Receivables Turnover falls in comparison to its industry or sector. The grey bar indicates the Receivables Turnover's extreme value range as defined by GuruFocus.



Biohaven Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Biohaven's Receivables Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Receivables Turnover (A: Dec. 2021 )
=Revenue / Average Total Inventories
=Revenue (A: Dec. 2021 ) / ((Accounts Receivable (A: Dec. 2020 ) + Accounts Receivable (A: Dec. 2021 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

Biohaven's Receivables Turnover for the quarter that ended in Sep. 2022 is calculated as

Receivables Turnover (Q: Sep. 2022 )
=Revenue / Average Total Inventories
=Revenue (Q: Sep. 2022 ) / ((Accounts Receivable (Q: Jun. 2022 ) + Accounts Receivable (Q: Sep. 2022 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven  (NYSE:BHVN) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


Biohaven Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Biohaven's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Comparable Companies
Traded in Other Exchanges
N/A
Address
215 Church Street, New Haven, CT, USA, 06510
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Executives
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

Other Sources

Why Biohaven Stock Is Soaring Today

By Yahoo Finance 2022-10-04